Amneal Pharmaceuticals
AMRX
144 hedge funds and large institutions have $135M invested in Amneal Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 47 increasing their positions, 48 reducing their positions, and 21 closing their positions.
128% more call options, than puts
Call options by funds: $66K | Put options by funds: $29K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 48
3.41% less ownership
Funds ownership: 67.29% → 63.88% (-3.4%)
8% less funds holding
Funds holding: 156 → 144 (-12)
33% less capital invested
Capital invested by funds: $202M → $135M (-$67.5M)
57% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Eversept Partners
New York
|
+$8.67M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.74M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$996K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$688K |
| 5 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$648K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$7.64M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$5.26M |
| 3 |
Millennium Management
New York
|
-$3.82M |
| 4 |
O
OrbiMed
New York
|
-$3.15M |
| 5 |
IA
IFP Advisors
Tampa,
Florida
|
-$1.97M |
AMRX Hedge Fund Activity: Q1 2023 in Review
144 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q1 2023, worth a combined $135M — down 33% from $202M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of AMRX and 9 opened new positions — a net loss of 12 holders — while 48 trimmed existing stakes and 47 added.
The largest buyer was Eversept Partners, adding an estimated $8.67M. The largest seller was Morgan Stanley, cutting an estimated $7.64M.
- 144 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q1 2023, down from 156 in Q4 2022.
- Funds reported $135M of Amneal Pharmaceuticals stock for Q1 2023, down 33% quarter-over-quarter.
- 9 funds opened new Amneal Pharmaceuticals positions in Q1 2023 and 21 closed out, a net change of -12 holders.
- The largest Amneal Pharmaceuticals buyer in Q1 2023 was Eversept Partners, an estimated $8.67M added.
- The largest Amneal Pharmaceuticals seller in Q1 2023 was Morgan Stanley, an estimated $7.64M sold.
Based on aggregated 13F filings for Q1 2023.